“Our goal is to help biologics researchers break free from tools that just don’t cut it,” Taegen Clary from Unchained Labs told us.
“We are always looking to add more biologics focused tools to our portfolio.”
Unchained Lab's previous acquisitions include Avacta Analytical (the UNit), Avia Biosystems (the HUNK), and Avid Nano (the pUNk), in this order.
The Freeslate acquisition leverages the company's experience partnering with Biopharma for more than 20 years, and knowledge of helping researcher’s overcome common drug development bottlenecks through configurable automation solutions.
The new FormPrep platform automates biologic formulation preparation and generates up to 12 formulations per day with 20 minutes of prep time – manually, this would take 2-4 days.
“[The] platform, that completely automates the process of creating biologic formulations, is a perfect fit with our biologic characterization tools,” said Clary.
“We’re helping our customers create more formulations than ever with Form Prep and learn more about which formulations will keep their proteins stable with our UNit, HUNK and pUNk platforms. We have built the best portfolio of tools out there for biologics formulation development.”
Unchained Labs CEO and founder, Tim Harkness, described combining Freeslate’s scale with Unchained Labs growth and capital as “a game-changer.”
"Freeslate has made great progress over the past five years, and this transaction makes great sense for the business, our customers and employees," said John Senaldi, President and CEO of Freeslate. "Unchained Labs shares Freeslate's commitment to customer success and I'm confident the business is in the right hands."
Unchained Labs has grown to 110 employees, and has accrued more than $25m in annual revenue in just over a year.
As part of this transaction, the company raised $25m in a Series B financing with help from the original syndicate partners, Novo Ventures, Canaan Partners, and TPG Biotech.